Company Filing History:
Years Active: 2025
Title: The Innovative Contributions of Christopher Todd French
Introduction
Christopher Todd French is a notable inventor based in Los Angeles, California. He has made significant strides in the field of anti-infective research, particularly focusing on gram-negative pathogens. His work addresses critical health challenges posed by these pathogens, which are known for causing severe human infections.
Latest Patents
Christopher Todd French holds a patent for the discovery of novel anti-infectives targeting gram-negative pathogens. His research highlights the importance of intercellular spread in the pathogenesis of these pathogens, specifically Bp and Bm, which are classified as Tier-1 select pathogens. The patent details a high-throughput cell-based phenotypic assay that screened approximately 220,000 small molecules. This screening identified 268 hits, with 32 of these compounds demonstrating the ability to disrupt intercellular spread by Bp and/or Bm. In preclinical studies using a murine model of respiratory melioidosis, several of these agents proved to be significantly more effective than ceftazidime, the current standard treatment, in improving survival rates and reducing bacterial counts in major organs.
Career Highlights
Christopher Todd French is affiliated with the University of California, where he continues to advance his research in infectious diseases. His innovative approach to drug discovery has positioned him as a key figure in the fight against antibiotic-resistant infections. His work not only contributes to scientific knowledge but also has the potential to save lives through the development of new therapeutic options.
Collaborations
He has collaborated with esteemed colleagues such as Philip Bulterys and Jeffery F Miller, further enhancing the impact of his research through shared expertise and resources.
Conclusion
Christopher Todd French's contributions to the field of anti-infective research exemplify the critical role of innovation in addressing public health challenges. His patent and ongoing research efforts are paving the way for new treatments that could significantly improve patient outcomes.